Learn about the latest advances in medical therapies and drug-delivery methods aimed to improve patient compliance and prevent vison loss. Faculty will discuss the latest MIGS technologies and the ideal timing of surgical interventions. Learn how to educate patients, set expectations, and co-manage today’s glaucoma patients.
This activity is supported by unrestricted educational grants from Alcon and Sight Sciences.
Upon completion of this activity, the participant should be able to:
Sponsored by: 
Evolve Medical Education LLC (Evolve) is a COPE-accredited administrator.
This activity, COPE Activity Number 124341, is accredited by COPE for continuing education for optometrists. This course is approved for 1 hour of CE.
Course #: 79234-GL
Activity #: 124341
COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Cecelia C. Koetting, OD, FAAO, Dipl ABO
Hines Sight
Denver, CO
Thomas M. Chester, OD, FAAO
Clinical Director
Cleveland Eye Clinic
Brecksville, OH
Ahmad M. Fahmy, OD, FAAO, Dipl ABO
Director of Optometric Services
Minnesota Eye Consultants
Bloomington, MN
Leslie O’Dell, OD, FAAO
Medical Director
Director of Clinical Research
Medical Optometry America
York, PA
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Cecelia C. Koetting, OD, FAAO, Dipl ABO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Aldeyra, Allergan, Avellino, Bruder, Dompé, Eyevance, Glaukos, Kala Pharmaceuticals, Orasis, OysterPoint, RVL, and Thea. Grant/Research Support: Johnson & Johnson Vision. Speaker's Bureau: Alcon, Dompé, Eyevance, OysterPoint, and RVL.
Thomas M. Chester, OD, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Allergan, Dompé, Kala Pharmaceuticals, Novartis, Oyster Point Pharma, and Sight Sciences. Grant/Research Support: Ocular Therapeutix and Sight Sciences. Speaker's Bureau: Sight Sciences. Stock/Shareholder: Sight Sciences.
Ahmad M. Fahmy, OD, FAAO, Dipl ABO, has had a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Allergan, Kala Pharmaceuticals, and Sun Pharmaceutical Industries. Speaker's Bureau: Allergan, BioTissue, NuSight Medical, and Sight Sciences.
Leslie O’Dell, OD, FAAO, has had a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Alcon, Alderya, Allergan, Bausch + Lomb, EyeDetech, Eye Eco, Johnson & Johnson Vision, Kala Pharmaceuticals, Novartis, Ocuphire, Oyster Point, Sight Sciences, Sun Pharmaceutical Industries, and Tarsus Pharmaceuticals. Speaker's Bureau: Aerie Pharmaceuticals, Alcon, Allergan/AbbVie, Bausch + Lomb, Kala Pharmaceuticals, Oyster Point Pharma, and Sun Pharmaceutical Industries. Stock/Shareholder: Eyes are the Story, EyeDetech, and Medical Optometry America.
The Evolve and The Fundingsland Group staff, planners, and reviewers have no financial relationships with ineligible companies.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group, Alcon, or Sight Sciences.
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Douglas K. Devries, OD
Cecelia Koetting, OD, FAAO
Douglas K. Devries, OD
Cecelia Koetting, OD, FAAO
Douglas K. Devries, OD
Cecelia Koetting, OD, FAAO
Douglas K. Devries, OD
Cecelia Koetting, OD, FAAO
